• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TRIM5 基因编辑降低了人 T 淋巴细胞对 HIV-1 的易感性。

Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1.

机构信息

Department of Medical Biology, Université du Québec à Trois-Rivières, Trois-Rivières, QC G9A 5H7, Canada.

出版信息

Viruses. 2020 Dec 25;13(1):24. doi: 10.3390/v13010024.

DOI:10.3390/v13010024
PMID:33375604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7824555/
Abstract

Tripartite-motif-containing protein 5 isoform α (TRIM5α) is a cytoplasmic antiretroviral effector upregulated by type I interferons (IFN-I). We previously showed that two points mutations, R332G/R335G, in the retroviral capsid-binding region confer human TRIM5α the capacity to target and strongly restrict HIV-1 upon overexpression of the mutated protein. Here, we used clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-mediated homology-directed repair (HDR) to introduce these two mutations in the endogenous human TRIM5 gene. We found 6 out of 47 isolated cell clones containing at least one HDR-edited allele. One clone (clone 6) had both alleles containing R332G, but only one of the two alleles containing R335G. Upon challenge with an HIV-1 vector, clone 6 was significantly less permissive compared to unmodified cells, whereas the cell clones with monoallelic modifications were only slightly less permissive. Following interferon (IFN)-β treatment, inhibition of HIV-1 infection in clone 6 was significantly enhanced (~40-fold inhibition). TRIM5α knockdown confirmed that HIV-1 was inhibited by the edited TRIM5 gene products. Quantification of HIV-1 reverse transcription products showed that inhibition occurred through the expected mechanism. In conclusion, we demonstrate the feasibility of potently inhibiting a viral infection through the editing of innate effector genes. Our results also emphasize the importance of biallelic modification in order to reach significant levels of inhibition by TRIM5α.

摘要

三结构域蛋白 5 异构体 α(TRIM5α)是一种细胞质抗病毒效应物,可被 I 型干扰素(IFN-I)上调。我们之前曾表明,在突变蛋白过表达时,位于逆转录病毒衣壳结合区的两个点突变 R332G/R335G 赋予了人类 TRIM5α靶向和强烈限制 HIV-1 的能力。在这里,我们使用簇状规则间隔短回文重复(CRISPR)-Cas9 介导的同源定向修复(HDR)在人类 TRIM5 基因的内源性基因中引入这两个突变。我们发现 47 个分离的细胞克隆中有 6 个至少含有一个 HDR 编辑等位基因。一个克隆(克隆 6)两个等位基因都含有 R332G,但只有两个等位基因中的一个含有 R335G。在受到 HIV-1 载体的挑战时,与未修饰的细胞相比,克隆 6 的允许性明显降低,而具有单等位基因修饰的细胞克隆则只是稍微不允许。在用干扰素(IFN)-β处理后,HIV-1 感染在克隆 6 中的抑制显著增强(~40 倍抑制)。TRIM5α 敲低证实了编辑的 TRIM5 基因产物抑制了 HIV-1。对 HIV-1 逆转录产物的定量显示,抑制是通过预期的机制发生的。总之,我们证明了通过编辑先天效应基因来有效抑制病毒感染的可行性。我们的结果还强调了双等位基因修饰对于通过 TRIM5α 达到显著抑制水平的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/e88ac018d2a6/viruses-13-00024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/16fd25309b96/viruses-13-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/82c1b8b648d3/viruses-13-00024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/b081200fe155/viruses-13-00024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/a28557d687d2/viruses-13-00024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/e88ac018d2a6/viruses-13-00024-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/16fd25309b96/viruses-13-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/82c1b8b648d3/viruses-13-00024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/b081200fe155/viruses-13-00024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/a28557d687d2/viruses-13-00024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ca/7824555/e88ac018d2a6/viruses-13-00024-g005.jpg

相似文献

1
Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1.TRIM5 基因编辑降低了人 T 淋巴细胞对 HIV-1 的易感性。
Viruses. 2020 Dec 25;13(1):24. doi: 10.3390/v13010024.
2
Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1.对人类TRIM5基因进行编辑,以引入具有抑制HIV-1潜力的突变。
PLoS One. 2018 Jan 26;13(1):e0191709. doi: 10.1371/journal.pone.0191709. eCollection 2018.
3
TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner.TRIM34 通过依赖于 TRIM5α 的方式限制 HIV-1 和 SIV 衣壳。
PLoS Pathog. 2020 Apr 13;16(4):e1008507. doi: 10.1371/journal.ppat.1008507. eCollection 2020 Apr.
4
A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV.一种可包装病毒的 CRISPR 筛选技术确定了介导干扰素抑制 HIV 的宿主因子。
Elife. 2018 Dec 6;7:e39823. doi: 10.7554/eLife.39823.
5
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.抗病毒限制因子TRIM5α与1型人类免疫缺陷病毒感染的遗传关联。
J Virol. 2006 Mar;80(5):2463-71. doi: 10.1128/JVI.80.5.2463-2471.2006.
6
Human TRIM5α: Autophagy Connects Cell-Intrinsic HIV-1 Restriction and Innate Immune Sensor Functioning.人类 TRIM5α:自噬连接细胞内固有 HIV-1 限制和先天免疫传感器功能。
Viruses. 2021 Feb 19;13(2):320. doi: 10.3390/v13020320.
7
General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.TRIM5蛋白识别逆转录病毒衣壳模式的通用模型。
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01563-17. Print 2018 Feb 15.
8
Cyclophilin A protects HIV-1 from restriction by human TRIM5α.亲环素 A 保护 HIV-1 免受人源 TRIM5α 的限制。
Nat Microbiol. 2019 Dec;4(12):2044-2051. doi: 10.1038/s41564-019-0592-5. Epub 2019 Oct 21.
9
Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA.破坏 HIV-1 衣壳形成导致 cGAS 对病毒 DNA 的感应。
EMBO J. 2020 Oct 15;39(20):e103958. doi: 10.15252/embj.2019103958. Epub 2020 Aug 27.
10
K63-Linked Ubiquitin Is Required for Restriction of HIV-1 Reverse Transcription and Capsid Destabilization by Rhesus TRIM5α.K63 连接泛素对于恒河猴 TRIM5α 限制 HIV-1 逆转录和衣壳解聚是必需的。
J Virol. 2019 Jun 28;93(14). doi: 10.1128/JVI.00558-19. Print 2019 Jul 15.

引用本文的文献

1
New hope and promise with CRISPR-Cas9 technology for the treatment of HIV.CRISPR-Cas9技术为治疗艾滋病带来新希望与前景。
Funct Integr Genomics. 2025 May 24;25(1):108. doi: 10.1007/s10142-025-01613-1.
2
A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.一项靶向CRISPR筛选确定ETS1为HIV-1潜伏的调节因子。
PLoS Pathog. 2025 Apr 8;21(4):e1012467. doi: 10.1371/journal.ppat.1012467. eCollection 2025 Apr.
3
Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells.

本文引用的文献

1
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor.HIV-1 衣壳抑制剂的结构和机制基础。
Science. 2020 Oct 16;370(6514):360-364. doi: 10.1126/science.abb4808.
2
Increasing CRISPR/Cas9-mediated homology-directed DNA repair by histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂增强 CRISPR/Cas9 介导的同源定向 DNA 修复。
Int J Biochem Cell Biol. 2020 Aug;125:105790. doi: 10.1016/j.biocel.2020.105790. Epub 2020 Jun 10.
3
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.用于 HIV-1 预防的疫苗和广泛中和抗体。
通过CRISPR/Cas9或Cas12a介导的原代人T细胞敲入提高基因编辑效率
Biomedicines. 2024 Jan 6;12(1):119. doi: 10.3390/biomedicines12010119.
4
Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer.Schlafen 家族是一个预后生物标志物,与胃癌的免疫浸润相对应。
Front Immunol. 2022 Aug 25;13:922138. doi: 10.3389/fimmu.2022.922138. eCollection 2022.
5
Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation.CRISPR-Cas9基因编辑技术在HIV宿主因子发现与验证中的应用
Pathogens. 2022 Aug 9;11(8):891. doi: 10.3390/pathogens11080891.
6
Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.CRISPR/Cas 基因组编辑工具在 HIV 治疗中的应用:实现精确修饰和多层次保护。
Front Cell Infect Microbiol. 2022 May 25;12:880030. doi: 10.3389/fcimb.2022.880030. eCollection 2022.
7
Updates on CRISPR-based gene editing in HIV-1/AIDS therapy.基于CRISPR的基因编辑在HIV-1/艾滋病治疗中的进展
Virol Sin. 2022 Feb;37(1):1-10. doi: 10.1016/j.virs.2022.01.017. Epub 2022 Jan 19.
8
The Interplay of HIV and Autophagy in Early Infection.早期感染中HIV与自噬的相互作用
Front Microbiol. 2021 Apr 28;12:661446. doi: 10.3389/fmicb.2021.661446. eCollection 2021.
Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.
4
Measuring the Success of HIV-1 Cure Strategies.评估 HIV-1 治愈策略的效果。
Front Cell Infect Microbiol. 2020 Apr 7;10:134. doi: 10.3389/fcimb.2020.00134. eCollection 2020.
5
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.HIV-1 潜伏库的生物学特性及其对治愈策略的影响。
Cell Host Microbe. 2020 Apr 8;27(4):519-530. doi: 10.1016/j.chom.2020.03.014.
6
Curing HIV: Seeking to Target and Clear Persistent Infection.治愈 HIV:寻求靶向和清除持续性感染。
Cell. 2020 Apr 2;181(1):189-206. doi: 10.1016/j.cell.2020.03.005. Epub 2020 Mar 26.
7
TRIM5α self-assembly and compartmentalization of the HIV-1 viral capsid.TRIM5α 自我组装和 HIV-1 病毒衣壳的区室化。
Nat Commun. 2020 Mar 11;11(1):1307. doi: 10.1038/s41467-020-15106-1.
8
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.长效卡替拉韦和利匹韦林维持治疗 HIV-1 抑制。
N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4.
9
DNA repair protein RAD51 enhances the CRISPR/Cas9-mediated knock-in efficiency in brain neurons.DNA 修复蛋白 RAD51 增强了脑神经元中 CRISPR/Cas9 介导的基因敲入效率。
Biochem Biophys Res Commun. 2020 Apr 9;524(3):621-628. doi: 10.1016/j.bbrc.2020.01.132. Epub 2020 Feb 4.
10
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.依巴斯汀:在多重耐药性 HIV-1 感染中的应用评价。
Drugs. 2020 Feb;80(2):189-196. doi: 10.1007/s40265-020-01258-3.